Home
Apnimed, Inc.

Apnimed, Inc. Market Share Analysis for May 2026

Learn about AD109 (aroxybutynin atomoxetine) and how it could address the neuromuscular cause of OSA. The potential power of AD109 is in a pill.

Health > Biotechnology and Pharmaceuticals

Domainapnimed.com

Year Founded2017

Employees51 - 200

Annual Revenue$5M - $10M

Apnimed, Inc.

Apnimed, Inc. (including company regionals)

apnimed.com

See more website traffic and engagement information

Apnimed, Inc. Revenue up to May 2026 is 5M - 10M

revenue generated by Apnimed, Inc. top domains

Apnimed, Inc. top domains revenue over 3 years

Revenue for Apnimed, Inc. top domains

apnimed.com5M - 10M

See more with Sales Intelligence

Total visits to Apnimed, Inc.'s top domains

Understand Apnimed, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apnimed.com31.5K

See more with Sales Intelligence

Avg. visit duration in Apnimed, Inc.'s top domains

Analyze Apnimed, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apnimed.com00:00:50

See more with Sales Intelligence

Avg. pageviews on Apnimed, Inc.'s top domains

See how Apnimed, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apnimed.com1.95

See more with Sales Intelligence

Apnimed, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

ensodata.comCompany NameEnsoDataEmployees51 - 200HQUnited States, Wisconsin, MadisonAnnual revenue$2M - $5MTotal visits5.5KHealth > Health - Other

Top technologies used by Apnimed, Inc.

These are the website technologies, by industry, used by Apnimed, Inc. top domains

Advertising (7)

Google Adsense

Widget (6)

Twemoji

Conversion & Analytics (2)

Google Analytics

Email Services (2)

Microsoft Exchange Online

More Technologies

9

See all

News & Signals from Apnimed, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApnimed Inc. hired Kevin Lind as chief executive officer on Jun 2nd '26.Apnimed has appointed biotechnology executive Kevin Lind as chief executive officer, positioning the late-stage pharmaceutical company for its next phase of growth as it advances its lead obstructive sleep apnea treatment candidate through regulatory review and toward potential commercialization.

NewsApnimed Inc. attended event American Thoracic Society (ATS) 2026 International Conference on May 15th '20.Apnimed announces three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference.

NewsApnimed Inc. receives financing of $50M in credit facility.* Apnimed entered a credit facility for up to $150 million with HealthCare Royalty Partners, receiving an initial $50 million at closing.